ASCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

Jonathan W. Friedberg, MD, University of Rochester, Rochester, NY, USA ...

JCO Journals have adopted a format-free submission policy (EZSubmit). New submissions are not scrutinized for compliance with our formatting guidelines (reference style, order of components, figure ...

JCO Journals employ a single-blind review process. Reviewers know the identity of the authors, but authors do not know the identity of the reviewers. Approximately 1/3 of submissions are rejected ...

All content dealing with understanding the provision of care—the mechanics of practice, care delivery, quality improvement, value, and equity—is the purview of JCO OP. JCO OP also addresses an ...

To wrap up 2024, we proudly present the Top 5 articles from each JCO Journal. The editors and staff are grateful to all of our authors for choosing JCO Journals to publish their work. Meric-Bernstam ...

JCO OA follows a continuous publication model. JCO OA articles are published online as soon as they are ready. No formal issues are published, though articles may be grouped in thematic collections or ...

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 ...

Journal of Clinical Oncology’s Featured Abstract Collections are designed to provide authoritative, yet concise, information on key abstracts from ASCO meetings. The ASCO AM 2023 Featured Abstracts ...

Despite recent momentum in the field, the treatment of patients with uCRLM remains heterogeneous and center-dependent. In the United States (US), few transplant centers offer protocols, and multimodal ...

Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...